The results of the use of etravirine within 48 weeks in patients in Saint-Petersburg in real clinical practice
https://doi.org/10.22625/2072-6732-2022-14-1-78-86
Abstract
The aim of the work was to evaluate the efficacy, safety and tolerability of etravirine-containing regimens in patients with treatment experience in real clinical practice.
Materials and methods. A retrospective analysis of 300 outpatient records of HIV-infected patients with treatment experience, which were converted to regimens containing etravirine (ETR) as the third component, was performed. The reasons for switching to ETR-containing regimens were adverse events, comorbidities, and virological failure. The main criterion for the effectiveness of the scheme was the proportion of patients with an undetectable level of viral load at 48 weeks of treatment. Additional criteria for evaluating the effectiveness and safety of the scheme were the dynamics of the number of CD4-lymphocytes, the frequency and nature of adverse reactions.
Results. The proportion of patients with virologic suppression less than 50 kop/mL was 83% versus 77,3% at the time of switching (p<0.005). The percentage of patients with CD4-lymphocytes level >500 ctlls/um increased from 40,3% to 58%, and the percentage of patients with CD4 level <200 cells/um decrease more than twice from 13% to 6% (p<0.005). The mean level os ALT decreased significantly from 47,52±66,45 units/L to 42,65±55,18 units/L (p=0,019). The average level of total cholesterol decreased by 8.7% from 5,64±1,37 mmol/L to 5.15±0.98 mmol/L (p<0,001). The average BMI after switching to ETR did not change and amounted to 24,07±4,07, 24,2±4,05, respectively (p=0,347).
Conclusions. The results of this study confirm that etravirine is well tolerated and may be an option for patients who have HIV RNA suppression on ART but develop adverse reactions, and may also be part of a second-line ART regimen in patients who fail first-line regimen.
About the Authors
N. V. Sizova
Centers for AIDS and Other Infections Diseases
Russian Federation
Russian Federation
Saint-Petersburg
S. O. Majorova
Centers for AIDS and Other Infections Diseases
Russian Federation
Russian Federation
Saint-Petersburg
Yа. V. Alad’ina
Centers for AIDS and Other Infections Diseases
Russian Federation
Russian Federation
Saint-Petersburg
L. V. Denisenko
Centers for AIDS and Other Infections Diseases
Russian Federation
Russian Federation
Saint-Petersburg
References
1. Clinical guidelines of the Ministry of Health of the Russian Federation “HIV infection in adults”, 2020
2. US Food and Drug Administration. Etravirine. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022187. Accessed August 2, 2021.
3. Das K, Clark AD, Jr., Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. Journal of Medicinal Chemistry. 2004;47(10):2550–2560.
4. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitorresistant human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 2004;48(12):4680–4686.
5. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009;23(17):2289–2300.
6. Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type1-infected patients in the DUET-1 and DUET-2 trials. Antiviral Therapy. 2010;15(7):1045–1052.
7. Schöller-Gyüre M, Kakuda TN, Raoof A, de Smedt G, Hoetelmans RMW. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clinical Pharmacokinetics. 2009;48(9):561–574.
8. C. Scott, N. Khatib, M. Bower, B. G. Gazzard, and M. Nelson, “Etravirine use in clinical practice: 48-week data from a single-centre cohort” Journal of the International AIDS Society, vol. 11, supplement 1, article P49, 2008.
9. P. Echeverria, A. Bonjoch, J. Puig et al., “Pilot study to assess the efficacy and safety of switching protease inhibitor to once-daily etravirine in HIV-infected subjects with viral suppression (ETRA-SWITCH STUDY),” in Proceedings of the International Conference on Antimicrobial Agents and Chemotherapy (ICAAC ‘11), September 2011.
10. P. Monteiro, I. Perez, M. Laguno et al., “Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study,” Journal of Antimicrobial Chemotherapy, vol. 69, no. 3, pp. 742–748, 2014.
11. R. Calin, L. Paris, A. Simon et al., “Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy,” Antiviral Therapy, vol. 17, no. 8, pp. 1601–1604, 2012.
12. S. Nozza, L. Galli, F. Visco et al., “Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience,” AIDS, vol. 24, no. 6, pp. 924–928, 2010.
13. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 2010;24:503-514.
14. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT) JAMA. 1986;256(20):2823–2828
15. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev. 2006;8(4):191–203
16. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS and Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003.
17. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38.
18. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48
19. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009;23(17):2289–2300.
Review
For citations:
Sizova N.V., Majorova S.O., Alad’ina Y.V., Denisenko L.V. The results of the use of etravirine within 48 weeks in patients in Saint-Petersburg in real clinical practice. Journal Infectology. 2022;14(1):78-86. (In Russ.) https://doi.org/10.22625/2072-6732-2022-14-1-78-86
Views:
484
.png)
.png)
Email this article 